Dose-dense cisplatin/paclitaxel: A well-tolerated and highly effective chemotherapeutic regimen in patients with advanced ovarian cancer

European Journal of Cancer

Volumn 38, Issue 15, 2002, Pages 2005-2013

  De Jongh, F E ^a   De Wit, R ^a   Verweij, J ^a   Sparreboom, A ^a   Van den Bent, M J ^a   Stoter, G ^a   Van der Burg, M E L ^a  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

Author keywords

Cisplatin; Dose intensity; Ovarian cancer; Paclitaxel; Pharmacokinetics; Response; Toxicity; Weekly chemotherapy

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA ADDUCT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERANCE; FATIGUE; FEMALE; HUMAN; MONOTHERAPY; NEPHROTOXICITY; NEUROTOXICITY; OVARY CANCER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CISPLATIN; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PACLITAXEL;

EID: 0036791973     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(02)00242-3     Document Type: Article

References (29)

1. Piver M.S., Baker T.R., Piedmonte M., Sandecki A.M. Epidemiology and etiology of ovarian cancer. Semin. Oncol. 18:1991;177-185.
2. Thigpen J.T. Chemotherapy for advanced ovarian cancer. overview of randomized trials Semin. Oncol. 27(Suppl. 7):2000;11-16.
3. McGuire W.P., Hoskins W.J., Brady M.F.et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med. 334:1996;1-6.
4. Piccart M.J., Bertelsen K., James K.et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer. three-year results J. Natl. Cancer Inst. 92:2000;699-708.
5. Markman M., Rothman R., Hakes T.et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J. Clin. Oncol. 9:1991;389-393.
6. Van der Burg M.E.L., Hoff A.M., van Lent M., Rodenburg C.J., van Putten W.L.J., Stoter G. Carboplatin and cyclophosphamide salvage therapy for ovarian cancer patients relapsing after cisplatin combination chemotherapy. Eur. J. Cancer. 27:1991;248-250.
7. Thigpen J.T., Blessing J.A., Ball H., Hummel S.J., Barrett R.J. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy. a Gynecologic Oncology Group study J. Clin. Oncol. 12:1994;1748-1753.
8. Einzig A.I., Wiernik P.H., Sasloff J., Runowicz C.D., Goldberg G.L. Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma. J. Clin. Oncol. 10:1992;1748-1753.
9. Eisenhauer E.A., ten Bokkel Huinink W.W., Swenerton K.D.et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer. high-dose versus low-dose and long versus short infusion J. Clin. Oncol. 12:1994;2654-2666.
10. Van der Burg MEL, Logmans A, de Wit R, et al. Weekly high dose cisplatin and oral vepesid: a highly active regimen for ovarian cancer failing on or relapsing after conventional platinum containing combination chemotherapy. Proc ASCO 1996, 15, 285 (abstr 722).
11. De Jonge M.J.A., Loos W.J., Gelderblom H.et al. Phase I pharmacologic study of oral topotecan and intravenous cisplatin. sequence-dependent hematologic side effects J. Clin. Oncol. 18:2000;2104-2115.
12. De Jonge M.J.A., Verweij J., de Bruijn P.et al. Pharmacokinetic, metabolic and pharmacodynamic profiles in a dose escalation study of irinotecan and cisplatin. J. Clin. Oncol. 18:2000;195-203.
13. Mathijssen R.H.J., van Alphen R.J., de Jonge M.J.A.et al. Sparse-data set analysis for irinotecan and SN-38 pharmacokinetics in cancer patients co-treated with cisplatin. Anticancer Drugs. 10:1999;9-16.
14. Sparreboom A, Loos WJ, van der Burg MEL, et al. Effect of paclitaxel dose on the pharmacokinetics of cisplatin. Proc AACR 2001, 42, 537 (abstr 2892).
15. De Jongh F.E., Verweij J., Loos W.J.et al. Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure. J. Clin. Oncol. 19:2001;3733-3739.
16. Schellens J.H.M., Ma J., Planting A.S.T.et al. Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours. Br. J. Cancer. 73:1996;1569-1575.
17. McGuire W.P. High-dose chemotherapeutic approaches to ovarian cancer management. Semin. Oncol. 27(Suppl. 7):2000;41-46.
18. Fennelly D. The role of high-dose chemotherapy in the management of advanced ovarian cancer. Curr. Opin. Oncol. 8:1996;415-425.
19. Ozols R.F., Ostchega Y., Myers C.E., Young R.C. High-dose cisplatin in hypertonic saline in refractory ovarian cancer. J. Clin. Oncol. 3:1985;1246-1250.
20. Kaye S.B., Lewis S.B., Paul J.et al. Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer. Lancet. 340:1992;329-333.
21. Ngan H.Y.S., Choo Y.C., Cheung M.et al. A randomized study of high-dose versus low-dose cis-platinum combined with cyclophosphamide in the treatment of advanced ovarian cancer. Chemother. 35:1989;221-227.
22. Kohn E.C., Sarosy G., Bicher A.et al. Dose-intense taxol. high response rate in patients with platinum-resistant recurrent ovarian cancer J. Natl. Cancer Inst. 86:1994;18-24.
23. Kohn E.C., Sarosy G.A., Davis P.et al. A phase I/II study of dose-intense paclitaxel with cisplatin and cyclophosphamide as initial therapy of poor-prognosis advanced-stage epithelial ovarian cancer. Gynecol. Oncol. 62:1996;181-191.
24. Markman M. Weekly paclitaxel in the management of ovarian cancer. Semin. Oncol. 27(Suppl. 7):2000;37-40.
25. Hilkens P.H.E., Van der Burg M.E.L., Moll J.W.B.et al. Neurotoxicity is not enhanced by increased dose intensities of cisplatin administration. Eur. J. Cancer. 31:1995;678-681.
26. Litterst C.L. Alterations in the toxicity of cis-dichlorodiammineplatinum-II and in tissue localization of platinum as a function of NaCl concentration in the vehicle of administration. Toxicol. Appl. Pharmacol. 61:1981;99-108.
27. Merouani A., Davidson S.A., Schrier R.W. Increased nephrotoxicity of combination taxol and cisplatin chemotherapy in gynecologic cancers as compared to cisplatin alone. Am. J. Nephrol. 17:1997;53-58.
28. De Vos A.I., Nooter K., Verweij J.et al. Differential modulation of cisplatin accumulation in leukocytes and tumor cell lines by the paclitaxel vehicle Cremophor EL. Ann. Oncol. 8:1997;1145-1150.
29. Neijt J.P., ten Bokkel Huinink W.W., Van der Burg M.E.L.et al. Long-term survival in ovarian cancer. Mature data from the Netherlands Joint Study Group for Ovarian Cancer. Eur. J. Cancer. 27:1991;1367-1372.